ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
47 announcements
Emcure Pharmaceuticals was assigned an ESG rating of 21 by NSE Sustainability Ratings for FY 2024-25. This independent assessment reflects its environmental and social performance.
Emcure surpassed $1B revenue in FY26, driven by strong international growth and high-end niche launches despite a temporary restructuring-led slowdown in their Zuventus portfolio.
Emcure Pharmaceuticals Limited recommended a final dividend of ₹0.36 per equity share for the financial year 2025-26. The dividend is subject to shareholder approval at the upcoming Annual General Meeting. The record date and AGM date will be communicated in due course.
Emcure Pharmaceuticals approved the re-appointment of Mr. Satish Mehta as MD for five years starting April 2027 and Mr. Mukund Gurjar as Executive Director for twelve months starting August 2026. The appointments were approved during the board meeting held on May 5, 2026, ensuring leadership continuity for the company.
Emcure Pharmaceuticals approved the re-appointment of Dr. Mukund Gurjar as Whole-time Director for one year and Mr. Satish Mehta as Managing Director for five years. The board meeting concluded on May 05, 2026. These leadership continuations aim to ensure management stability for the company's long-term growth plans.
Emcure Pharmaceuticals approved the re-appointment of Dr. Mukund Gurjar as Whole-time Director for one year and Mr. Satish Mehta as Managing Director for five years. These leadership extensions remain subject to shareholder approval.
Emcure crossed $1Bn revenue milestone in FY26, delivering 16.6% growth and margin expansion. Focus remains on scaling international markets and strategic domestic partnerships (Novo Nordisk, Sanofi, Roche).
Emcure Pharmaceuticals reported strong FY26 results with consolidated revenue growing 16.6% YoY to ₹9,203.54 Crore, crossing the $1 billion milestone. Reported PAT rose 33.1% to ₹941 Crore. International markets drove growth, up 22.2%, while domestic sales grew 10%. The Board recommended a final dividend of ₹3.60 per share.
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,470 Cr (+16.7% YoY) and net profit of ₹243.7 Cr (+23.6% YoY) for Q4 FY26.
Emcure Pharmaceuticals approved its FY26 audited results, reporting consolidated revenue of ₹9,204 Crore and PAT of ₹941 Crore. The board recommended a final dividend of ₹3.60 per share. Key leadership re-appointments include Mr. Satish Mehta as Managing Director for five years and Dr. Mukund Gurjar as Whole-time Director for one year.
Emcure Pharmaceuticals Limited has scheduled a Board Meeting for May 5, 2026. The board will consider audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until May 7, 2026.
Emcure Pharmaceuticals Limited has scheduled a Board Meeting for May 5, 2026. The Board will consider audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until May 7, 2026.
Emcure Pharmaceuticals has scheduled a Board Meeting on May 05, 2026. The board will consider audited financial results for the quarter and year ended March 31, 2026, and a final dividend recommendation. The trading window is closed until May 07, 2026.
Emcure Pharmaceuticals Limited announced that its members approved the appointment of Mr. C S Muralidharan as an Independent Director via Postal Ballot. The appointment is for a three-year term effective April 01, 2026. The remote e-voting process concluded on April 24, 2026, with results announced today.
Emcure Pharmaceuticals Limited announced the successful passage of a special resolution via postal ballot on April 24, 2026. Shareholders approved the appointment of Mr. C S Muralidharan as an Independent Director for a three-year term effective April 01, 2026. The voting process was conducted electronically and confirmed as fair by the scrutinizer.
Emcure Pharmaceuticals Limited announced the successful passage of a special resolution via postal ballot to appoint Mr. C S Muralidharan as an Independent Director. The resolution was passed with a 99.9999% majority effective April 24, 2026. The filing includes the formal voting results and Scrutinizer's Report.
Emcure Pharmaceuticals Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the period ending March 31, 2026. The certificate from RTA MUFG Intime India confirms that security certificates received for dematerialisation were processed and cancelled within prescribed timelines.